Fierce Pharma

As the FDA steadily churns out a stream of untitled [...]

Amid rapidly evolving media consumption habits and a federal push [...]

As Eli Lilly gears up to support its partnered athletes, [...]

Within the mammoth defense bill, the Biosecure Act has the [...]

“Following the withdrawal of Ocaliva from the U.S. market, we [...]

Tuesday, the U.S. regulator greenlit GSK’s depemokimab, an ultra-long-acting biologic, [...]

As both Novo Nordisk and Eli Lilly race to develop [...]

The FDA has approved Enhertu combined with Roche’s Perjeta as [...]

The FDA has signed off on Milestone Pharmaceuticals’ Cardamyst, a [...]

After three decades of no new antibiotics for the treatment [...]